Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 15Sarcoma 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Motor Activity 1Lung Neoplasms 1HER2-positive Breast Cancer 1HER2 Positive Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Breast Diseases 1Breast Cancer Female 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Exercise 3Control Groups 2pyrotinib 1Yoga 1Waiting Lists 1Trastuzumab 1Self-Help Groups 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1Neoadjuvant Therapy 1Mastectomy, Segmental 1Mammaplasty 1Educational Status 1Diet 1Culture Techniques 1Caloric Restriction 1Anesthesia, General 1Anesthesia, Conduction 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Breast Cancer Female × Trastuzumab × Clear all
NCT06035679 2025-03-12

Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

First Affiliated Hospital of Fujian Medical University

Phase NA Recruiting
30 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡